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 Vision Paper by the Editor-in-Chief 
 “ Knowledge-based (personalized) medicine ” instead 
of  “ evidence-based (cohort) medicine ” 
Applying nanoscience and computational science to create an effective, 
safe, curative and affordable medicine of the future 
 Patrick Hunziker 
 
 
 Medicine has moved from phenomenological diagnosis based 
on syndromes (i.e. a pattern of symptoms and clinical fi nd-
ings) to diagnosis based on imaging and on organ-specifi c 
biomarkers, typically assuming a homogenous population. 
This approach, which often identifi es a single disease entity 
by a single biomarker (like troponin for heart attack, procal-
citonin for bacterial infection in respiratory disease, and rapid 
diagnostic testing for malaria) has been highly successful in 
identifying frequent diseases and has paved the way to more 
effective therapy. However, predicting the course of disease 
in individuals is still a major challenge for clinical reality and 
experienced physicians refrain from predicting the future in 
a too assertive manner when consulting their patients. This 
is due to the fact that a seemingly clear disease entity like 
myocardial infarction is a continuum in space (location of 
infarct related artery), time (critical relevance of timing of 
reopening of occluded artery), severity, and individual fac-
tors (degree of subclinical atherosclerosis not related to the 
event, variability of coagulation system, response to drugs). 
This inability to predict leads to treatment of individuals 
who will not benefi t from therapy (like platelet inhibition by 
clopidogrel in clopidogrel nonresponders), while important 
side effects (e.g., allergic reaction) of drugs can occur even 
in the absence of patient-specifi c benefi ts due to the taking of 
a particular drug. 
 Time has come to assess disease not only in a  “ mono-
marker ” fashion, but to open our eyes to the individuality of 
each patient and his disease by identifying of the individual 
biological context (e.g., genetic variabilities in metabolism, 
immune system state, coagulation system), in its temporal 
dimension. 
 1.  The quest for nanoscience and computational-
science based tools for personalized patient 
management 
 Nanoscience based technologies for fast and deep genomic 
sequencing, for proteomic and metabolomic analysis will play 
a big role in understanding the many facets of a patient ’ s state. 
However, progressing beyond single biomarkers towards a 
more comprehensive understanding is a major challenge for 
current medical practice: recent developments towards  “ evi-
dence-based medicine ” and a guideline-driven practice have 
driven medical practice in the opposite direction: assuming 
that multicenter megatrials comprising a broad mix of patients 
would yield the ultimate truth about the value of single drugs 
for single disease entities, largely neglecting the individual-
ity of a patient. Also, daily practice is strongly infl uenced by 
simplistic  “ standard operating procedures ” because those are 
simple to memorize. 
 2.  The quest for computational science tools for 
personalized medicine in clinical practice 
 This implies that a key success factor for personalized med-
icine in clinical practice are tools that allow to draw valid 
and predictive conclusions from the complexities of a full 
genomic and proteomic assessment of a given patient, and 
that allow to choose not only a personalized drug, but also an 
optimized drug dose, drug schedule and therapy duration or 
an optimal drug combination based on suited disease mod-
els. An interdisciplinary effort combining clinical medicine, 
nanotech diagnosis, genomics, and computational science is 
required to develop such predictive models and to validate 
them in clinical practice. 
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 3.  The quest for more effective, safer, affordable 
therapies and a perspective of cure instead of 
disease suppression 
 The  “ number needed to treat ” (NNT) is an established number 
to quantify a therapeutic benefi t to patients and expresses the 
number of patients that need to be treated to prevent a single 
major event in a patient  (1) . If the NNT equals 1, each patient 
treated benefi ts from the therapy. In practice, NNTs between 
10 and  > 100 for common diseases like heart attack or hip 
fracture are common. Another number quantifying the ben-
efi t to the patient is  “ postponement ” , i.e. the average increase 
in time delay to the occurence of a major event in the entire 
treated population  (2) . Analysis of these numbers shows that 
in many therapies a minority of patients draw a major benefi t 
from treatment, but a majority of patient do not actually ben-
efi t signifi cantly, while still allowing the number or degree of 
side effects and the cost of drugs to increase. The limitation 
on today ’ s medicine is very visible in the fi eld of oncology, 
where cancer chemotherapy is often able to postpone death 
by cancer, but rarely able to cure it. Thus, it is evident that a 
major driver of cost in healthcare is our inability to predict 
who will benefi t as well as our inability to cure them. 
Nanomedicine is on the way to profoundly change the effi -
cacy/safety profi le of many drugs through targeted delivery 
based on molecular understanding in a personalized fashion. 
This is currently best visible in novel cancer therapies: by 
achieving high drug doses in diseased tissues while limiting 
drug concentration in remote, healthy tissues, it is possible to 
achieve cancer cures in mice at a signifi cantly higher success 
rate compared to conventional therapies, in particular if molecu-
lar targeting strategies are applied. Hopefully, we will see trans-
lation of these results (already visible in a limited number of 
clinical trials) to broad clinical practice soon. While oncology 
is a pioneering fi eld with respect to application of nanomedical 
therapies, there is a need to progress towards a curative approach 
also for other diseases of comparable severity (namely infl am-
mation/infection, cardiovascular disease, and brain diseases), of 
high prevalence, or of similar economic burden.
Today’s medicine is reasonably effective but also quite 
expensive, thereby limiting access to healthcare for important 
segments of the world population. While new developments in 
medicine always carry a price tag, the high “numbers needed 
to treat” in current medical practice show that there is also 
ample opportunity to save expenses by focusing therapies on 
those who will really profi t from them, made possible on the 
basis of a deeper knowledge and more detailed understanding 
of disease in individuals through nanoscience-enabled diag-
nostic tools. 
Moving from the currently dominant palliative treat-
ment schemes to persistent cure will also free up signifi cant 
resources from their currently ineffective use for more effec-
tive therapies. A transition from palliative to curative thera-
pies in the fi elds of cancer, cardiovascular disease, diabetes 
and dementia will thus not only allow us to spend more of our 
lifetime in good health but also enable a reduction of indirect 
health-related costs, which already now exceed direct health-
care spending.
Nanomedicine is the horizon, and it promises not only 
better and safer “standard” therapies but also a curative 
approach to important diseases and a highly cost-effi cient 
medical practice by spearheading a personalized, knowledge-
based medicine. 
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